Dr. Ravi on the Evolving Treatment Landscape of Advanced Bladder Cancer

Video

In Partnership With:

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Praful K. Ravi, MD, oncology fellow at Dana-Farber Cancer Institute, discusses the evolving treatment landscape of advanced bladder cancer.

Five years ago, the treatment of patients with advanced bladder cancer consisted only of chemotherapy options, Ravi says. Now, the paradigm includes a multitude of therapies including immunotherapy.

Pembrolizumab (Keytruda) and atezolizumab (Tecentriq) are approved for use in patients with locally advanced or metastatic bladder cancer, says Ravi. Moreover, pembrolizumab has demonstrated an overall survival benefit compared with chemotherapy in patients who have received platinum-based chemotherapy.

Additionally, targeted therapies with FGFR inhibitors and antibody-drug conjugates have been instrumental in expanding the landscape, Ravi explains.

In the future, personalization of therapy, as well as optimization of sequencing will be critical areas of research, concludes Ravi.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD